Deal aims to provide diabetes treatment to patients across the continent.
In an effort to provide life-saving treatment to people living with diabetes across the African continent, Novo Nordisk have officially announced a partnership with Aspen. As per the agreement, Aspen will focus on producing Insulin from its facilities in South Africa. Reportedly, the partnership will result in a production of 16 million vials of insulin, equivalent to the yearly consumption of 1.1 million people next year. Additionally, the company stated that this will increase to 4.1 million by 2026.
“We firmly believe that access to quality healthcare is a fundamental human right,” said Katrine DiBona, corporate VP, global public affairs and sustainability, Novo Nordisk. "We are committed to providing affordable human insulin to ensure access to quality treatments for even more people with diabetes in the African continent. At the same time, it is equally important for us that we are doing it in a sustainable way by focusing on local production.”
Reference: Novo Nordisk announces new partnership to supply human insulin to millions of people living with diabetes in the African continent. Novo Nordisk. September 19, 2023. Accessed September 20, 2023. https://www.novonordisk.com/news-and-media/latest-news/new-partnership-to-supply-human-insulin.html
Protecting Temperature-Sensitive Pharmaceuticals, Without Unnecessary Plastic Waste
March 24th 2025Advances in the life sciences are driving a significant increase in the number of temperature-sensitive pharmaceuticals. The packaging industry is meeting the moment with advances of its own, including high-performance, environmentally-friendly materials that allow life science companies meet stringent thermal requirements and ambitious CO2e reduction goals. In this episode, TemperPack’s CEO Peter Wells shares insights from working with life sciences to move to certified biobased, home compostable, and curbside recyclable shipping solutions.